• Male

Dr. A.G. Holleboom MD PhD

Position: Postdoc
Main activities: Patient care, Research
Specialisation: Endocrinology and Metabolism
foto
Focus of research:

Perturbed Lipid Pathways in Disorders of Protein Glycosylation and Golgi Trafficking

AMC themes: Cardiovascular Diseases, Metabolic disorders and gastrointestinal diseases
Departments: Internal Medicine: Endocrinology, Internal Medicine: Vascular Medicine
van den Boogert MAW, Rader DJ, Holleboom AG, New insights into the role of glycosylation in lipoprotein metabolism. CURR OPIN LIPIDOL 2017;28 (6):502-506 [PubMed]
Jansen JC, Cirak S, van Scherpenzeel M, Timal S, Reunert J, Rust S, Pérez B, Vicogne D, Krawitz P, Wada Y, Ashikov A, Pérez-Cerdá C, Medrano C, Arnoldy A, Hoischen A, Huijben K, Steenbergen G, Quelhas D, Diogo L, Rymen D, Jaeken J, Guffon N, Cheillan D, van den Heuvel LP, Maeda Y, Kaiser O, Schara U, Gerner P, van den Boogert MAW, Holleboom AG, Nassogne MC, Sokal E, Salomon J, van den Bogaart G, Drenth JPH, Huynen MA, Veltman JA, Wevers RA, Morava E, Matthijs G, Foulquier F, Marquardt T, Lefeber DJ, CCDC115 Deficiency Causes a Disorder of Golgi Homeostasis with Abnormal Protein Glycosylation. AM J HUM GENET 2016;98 (2):310-321 [PubMed]
Jansen JC, Timal S, van Scherpenzeel M, Michelakakis H, Vicogne D, Ashikov A, Moraitou M, Hoischen A, Huijben K, Steenbergen G, van den Boogert MAW, Porta F, Calvo PL, Mavrikou M, Cenacchi G, van den Bogaart G, Salomon J, Holleboom AG, Rodenburg RJ, Drenth JPH, Huynen MA, Wevers RA, Morava E, Foulquier F, Veltman JA, Lefeber DJ, TMEM199 Deficiency Is a Disorder of Golgi Homeostasis Characterized by Elevated Aminotransferases, Alkaline Phosphatase, and Cholesterol and Abnormal Glycosylation. AM J HUM GENET 2016;98 (2):322-330 [PubMed]
Ljunggren SA, Levels JHM, Hovingh K, Holleboom AG, Vergeer M, Argyri L, Gkolfinopoulou C, Chroni A, Sierts JA, Kastelein JJ, Kuivenhoven JA, Lindahl M, Karlsson H, Lipoprotein profiles in human heterozygote carriers of a functional mutation P297S in scavenger receptor class B1. BBA-MOL CELL BIOL L 2015;1851 (12):1587-1595 [PubMed]
Bochem AE, Holleboom AG, Romijn JA, Hoekstra M, Dallinga GM , Motazacker MM, Hovingh GK, Kuivenhoven JA, Stroes ESG, Adrenal Function in females with low plasma HDL-C due to mutations in ABCA1 and LCAT. PLOS ONE 2014;9 (5):e90967 [PubMed]
Kuroda M, Holleboom AG, Stroes ESG, Asada S, Aoyagi Y, Kamata K, Yamashita S, Ishibashi S, Saito Y, Bujo H, Lipoprotein subfractions highly associated with renal damage in familial lecithin:cholesterol acyltransferase deficiency. ARTERIOSCL THROM VAS 2014;34 (8):1756-1762 [PubMed]
Ljunggren S, Levels JHM, Turkina MV, Sundberg S, Bochem AE, Hovingh K, Holleboom AG, Lindahl M, Kuivenhoven JA, Karlsson H, ApoA-I mutations, L202P and K131del, in HDL from heterozygotes with low HDL-C. PROTEOM CLIN APPL 2014;8 (3-4):241-250 [PubMed]
Bochem AE, Holleboom AG, Romijn JA, Hoekstra M, Dallinga-Thie GM, Motazacker MM, Hovingh GK, Kuivenhoven JA, Stroes ESG, High density lipoprotein as a source of cholesterol for adrenal steroidogenesis: a study in individuals with low plasma HDL-C. J LIPID RES 2013;54 (6):1698-1704 [PubMed]
Bochem AE, van Wijk DF, Holleboom AG, Duivenvoorden R, Motazacker MM, Dallinga-Thie GM, de Groot E, Kastelein JJP, Nederveen AJ, Hovingh GK, Stroes ESG, ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. EUR HEART J 2013;34 (4):286-291 [PubMed]
Holleboom AG, Jakulj L, Franssen R, Decaris J, Vergeer M, Koetsveld J, Luchoomun J, Glass A, Hellerstein MK, Kastelein JJP, Hovingh GK, Kuivenhoven JA, Groen AK, Turner SM, Stroes ESG, In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1. J LIPID RES 2013;54 (7):1964-1971 [PubMed]
Stoekenbroek RM, van den Bergh Weerman MA, Hovingh GK, Potter van Loon BJ, Siegert CEH, Holleboom AG, Familial LCAT deficiency: from renal replacement to enzyme replacement. NETH J MED 2013;71 (1):29-31 [PubMed]
Holleboom AG, Daniil G, Fu X, Zhang R, Hovingh GK, Schimmel AW, Kastelein JJP, Stroes ESG, Witztum JL, Hutten BA, Tsimikas S, Hazen SL, Chroni A, Kuivenhoven JA, Lipid Oxidation in Carriers of Lecithin: Cholesterol Acyltransferase Gene Mutations. ARTERIOSCL THROM VAS 2012;32 (12):3066-+ [PubMed]
Sonneveld ME, Zinkstok SM, Nellen FJB, Holleboom AG, Tuberculous meningitis: treat upon suspicion. BMJ CASE REP 2012;2012:bcr2012006627 [PubMed]
Steiner C, Holleboom AG, Karuna R, Motazacker MM, Kuivenhoven JA, Frikke-Schmidt R, Tybjaerg-Hansen A, Rohrer L, Rentsch KM, von Eckardstein A, Lipoprotein distribution and serum concentrations of 7 alpha-hydroxy-4-cholesten-3-one and bile acids: effects of monogenic disturbances in high-density lipoprotein metabolism. CLIN SCI 2012;122 (7-8):385-396 [PubMed]
van den Bogaard B, Holleboom AG, Duivenvoorden R, Hutten BA, Kastelein JJP, Hovingh GK, Kuivenhoven JA, Stroes ESG, van den Born BJH, Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness. ATHEROSCLEROSIS 2012;225 (2):481-485 [PubMed]
Daniil G, Phedonos AAP, Holleboom AG, Motazacker MM, Argyri L, Kuivenhoven JA, Chroni A, Characterization of antioxidant/anti-inflammatory properties and apoA-I-containing subpopulations of HDL from family subjects with monogenic low HDL disorders. CLIN CHIM ACTA 2011;412 (13-14):1213-1220 [PubMed]
den Ruijter HM, Franssen R, Verkerk AO, van Wijk DF, Vaessen SF, Holleboom AG, Levels JH, Opthof T, Sungnoon R, Stroes ES, Kuivenhoven JA, Coronel R, Reconstituted High-Density Lipoprotein Shortens Cardiac Repolarization. J AM COLL CARDIOL 2011;58 (1):40-44 [PubMed]
Duivenvoorden R, Holleboom AG, van den Bogaard B, Nederveen AJ, de Groot E, Hutten BA, Schimmel AW, Hovingh GK, Kastelein JJP, Kuivenhoven JA, Stroes ESG, Cholesterol Acyltransferase Gene Mutations Have Accelerated Atherogenesis as Assessed by Carotid 3.0-T Magnetic Resonance Imaging Carriers of Lecithin. J AM COLL CARDIOL 2011;58 (24):2481-2487 [PubMed]
Holleboom AG. Genetic disorders of HDL metabolism: from model to mechanism. s.l.: s.n.; 2011. 422p. ISBN 9789461081735 [UvA Dissertations Online] Proefschrift Universiteit van Amsterdam. (Promotor(s): Stroes ESG, Kastelein JJP; copromotor(s): Kuivenhoven JA, Hovingh GK)
Holleboom AG, Karlsson H, Lin RS, Beres TM, Sierts JA, Herman DS, Stroes ESG, Aerts JM, Kastelein JJP, Motazacker MM, Dallinga-Thie GM, Levels JHM, Zwinderman AH, Seidman JG, Seidman CE, Ljunggren S, Lefeber DJ, Morava E, Wevers RA, Fritz TA, Tabak LA, Lindahl M, Hovingh GK, Kuivenhoven JA, Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. CELL METAB 2011;14 (6):811-818 [PubMed]
Holleboom AG, Kuivenhoven JA, Peelman F, Schimmel AW, Peter J, Defesche JC, Kastelein JJP, Hovingh GK, Stroes ES, Motazacker MM, High prevalence of mutations in LCAT in patients with low HDL cholesterol levels in The Netherlands: identification and characterization of eight novel mutations. HUM MUTAT 2011;32 (11):1290-1298 [PubMed]
Holleboom AG, Kuivenhoven JA, van Olden CC, Peter J, Schimmel AW, Levels JH, Valentijn RM, Vos P, Defesche JC, Kastelein JJP, Hovingh GK, Stroes ESG, Hollak CEM, Proteinuria in early childhood due to familial LCAT deficiency caused by loss of a disulfide bond in lecithin:cholesterol acyl transferase. ATHEROSCLEROSIS 2011;216 (1):161-165 [PubMed]
Karuna R, Holleboom AG, Motazacker MM, Kuivenhoven JA, Frikke-Schmidt R, Tybjaerg-Hansen A, Georgopoulos S, van Eck M, van Berkel TJC, von Eckardstein A, Rentsch KM, Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism. ATHEROSCLEROSIS 2011;214 (2):448-455 [PubMed]
Karuna R, Park R, Othman A, Holleboom AG, Motazacker MM, Sutter I, Kuivenhoven JA, Rohrer L, Matile H, Hornemann T, Stoffel M, Rentsch KM, von Eckardstein A, Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. ATHEROSCLEROSIS 2011;219 (2):855-863 [PubMed]
Vergeer M, Korporaal SJA, Franssen R, Meurs I, Out R, Hovingh GK, Hoekstra M, Sierts JA, Dallinga-Thie GM, Motazacker MM, Holleboom AG, van Berkel TJC, Kastelein JJP, van Eck M, Kuivenhoven JA, Genetic Variant of the Scavenger Receptor BI in Humans. NEW ENGL J MED 2011;364 (2):136-145 [PubMed]
Candini C, Schimmel AW, Peter J, Bochem AE, Holleboom AG, Vergeer M, Dullaart RPF, Dallinga-Thie GM, Hovingh GK, Khoo KL, Fasano T, Bocchi L, Calandra S, Kuivenhoven JA, Motazacker MM, Identification and characterization of novel loss of function mutations in ATP-binding cassette transporter A1 in patients with low plasma high-density lipoprotein cholesterol. ATHEROSCLEROSIS 2010;213 (2):492-498 [PubMed]
Hildebrand RB, Lammers B, Meurs I, Korporaal SJA, De Haan W, Zhao Y, Kruijt JK, Praticò D, Schimmel AWM, Holleboom AG, Hoekstra M, Kuivenhoven JA, van Berkel TJC, Rensen PCN, van Eck M, Restoration of High-Density Lipoprotein Levels by Cholesteryl Ester Transfer Protein Expression in Scavenger Receptor Class B Type I (SR-BI) Knockout Mice Does Not Normalize Pathologies Associated With SR-BI Deficiency. ARTERIOSCL THROM VAS 2010;30 (7):1439-U419 [PubMed]
Holleboom AG, Kuivenhoven JA, Vergeer M, Hovingh GK, van Miert JN, Wareham NJ, Kastelein JJP, Khaw KT, Boekholdt SM, Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study. J LIPID RES 2010;51 (2):416-421 [PubMed]
Vergeer M, Holleboom AG, Kastelein JJP, Kuivenhoven JA, The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?. J LIPID RES 2010;51 (8):2058-2073 [PubMed]
Holleboom AG, Vergeer M, Hovingh GK, Kastelein JJ, Kuivenhoven JA, The value of HDL genetics. CURR OPIN LIPIDOL 2008;19 (4):385-394 [PubMed]
Gerbod-Giannone MC, Li Y, Holleboom A, Han S, Hsu LC, Tabas I, Tall AR, TNF alpha induces ABCA1 through NF-kappa B in macrophages and in phagocytes ingesting apoptotic cells. P NATL ACAD SCI USA 2006;103 (9):3112-3117 [PubMed]
Hovingh GK, Hutten BA, Holleboom AG, Petersen W, Rol P, Stalenhoef A, Zwinderman AH, de Groot E, Kastelein JJP, Kuivenhoven JA, Compromised LCAT function is associated with increased atherosclerosis. CIRCULATION 2005;112 (6):879-884 [PubMed]
Key publications

Holleboom AG, Karlsson H, Lin RS, Beres TM, Sierts JA, Herman DS, Stroes ESG, Aerts JM, Kastelein JJP, Motazacker MM, Dallinga-Thie GM, Levels JHM, Zwinderman AH, Seidman JG, Seidman CE, Ljunggren S, Lefeber DJ, Morava E, Wevers RA, Fritz TA, Tabak LA, Lindahl M, Hovingh GK, Kuivenhoven JA, Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. CELL METAB 2011;14 (6):811-818 [PubMed]
Holleboom AG, Daniil G, Fu X, Zhang R, Hovingh GK, Schimmel AW, Kastelein JJP, Stroes ESG, Witztum JL, Hutten BA, Tsimikas S, Hazen SL, Chroni A, Kuivenhoven JA, Lipid Oxidation in Carriers of Lecithin: Cholesterol Acyltransferase Gene Mutations. ARTERIOSCL THROM VAS 2012;32 (12):3066-+ [PubMed]
Holleboom AG, Jakulj L, Franssen R, Decaris J, Vergeer M, Koetsveld J, Luchoomun J, Glass A, Hellerstein MK, Kastelein JJP, Hovingh GK, Kuivenhoven JA, Groen AK, Turner SM, Stroes ESG, In vivo tissue cholesterol efflux is reduced in carriers of a mutation in APOA1. J LIPID RES 2013;54 (7):1964-1971 [PubMed]
Holleboom AG, Kuivenhoven JA, Peelman F, Schimmel AW, Peter J, Defesche JC, Kastelein JJP, Hovingh GK, Stroes ES, Motazacker MM, High prevalence of mutations in LCAT in patients with low HDL cholesterol levels in The Netherlands: identification and characterization of eight novel mutations. HUM MUTAT 2011;32 (11):1290-1298 [PubMed]
Holleboom AG, Kuivenhoven JA, Vergeer M, Hovingh GK, van Miert JN, Wareham NJ, Kastelein JJP, Khaw KT, Boekholdt SM, Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study. J LIPID RES 2010;51 (2):416-421 [PubMed]


All Publications

Curriculum Vitae

In 2011, dr. Holleboom obtained his PhD in Mendelian disorders of HDL metabolism, funded by a TopTalent grant from the Netherlands Organisation of Scientific Research (NWO). As a resident in Internal Medicine in the Academic Medical Center at the University of Amsterdam, he focuses on endocrinology with a special interest for genetic metabolic and genetic lipid disorders. His research focuses on the role of protein glycosylation and Golgi trafficking in lipid metabolism, mainly by studies of lipid disorders in congenital disorders of protein glycosylation. He is supported by a Veni postdoctoral fellowship from the Netherlands Organisation for Scientific Research (ZonMW) and has appointed a PhD student at the University of Amsterdam. In 2014-2015, he joined the lab of dr. D.J. Rader, University of Pennsylvania Philadelphia, to perform translational studies within the mentioned research focus, applying both immortalized pluripotent stem cells as well as CRISPR Cas9 editing. His alliance with the Rader lab is supported by a grant from the Netherlands Foundation for Cardiovascular Excellence. 

Supervision of academic staff

PhD student Ms. M.A.W. van den Boogert MD

2015 Best abstract, Gordon Conference Glycobiology

2014 PhD AMC graduate school PhD scholarship (205.000)

2013 Outstanding Research by an Early Career Investigator award, Council Arteriosclerosis Thrombosis and Vascular Biology, American Heart Association Sessions, Dallas

MSc students (completed supervision and writing of thesis)

Mr. A. van der Made 2010-2011 (GALNT2 and ABCA1 studies), now intern in Medicine

Mr. J. Legemate 2010-2011 (GALNT2 and ABCA1 studies), now intern in Medicine

Mr. C. van Olden 2010 (familial LCAT deficiency), now intern in Medicine

 Research grants and awards

2015: Metakids foundation (e 30.000)

2013: Excellence3Award from the Netherlands Foundation for Cardiovascular Excellence (50.000)

2012: NWO (Netherlands Organization for Scientific Research)/ZonMw postdoctoral VENI grant (250.000) for Genetic defects in protein glycosylation as cause of dyslipidemia

2012: Netherlands Foundation for Cardiovascular Excellence, Nominee Excellence3 Award (1.000)

2012: AMC Graduate School Publication award (€ 700) for Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man (Cell Metabolism 2011).

2007: NWO TopTalent grant for doctoral research (€180.000) on atheroprotection by HDL through anti-inflammatory effects.

2006: Dr. I. Snapper Award for medical students from Amsterdam and Utrecht involved in internal medicine research, patient care and education (€ 2500)

Lectures and seminars

2013 - Gordon Research Conference Glycobiology, Ventura California

- Japanese Atherosclerosis Society Tokyo (lecture Established versus preliminary drug targets for dyslipidemia: lessons from LCAT deficiency syndromes versus congenital defects of protein glycosylation)

2015

-        Complex Carbohydrate Research Center, University of Georgia, Athens GA

-        Lipoprotein Section, NHLBI, NIH, Bethesda MD

Consult via MedaCorp concerning therapy development for LCAT deficiency    

 

 

 

Research programmes
Other research related activities
  • Contribution to training of professionals, University of Amsterdam
Current research funding
  • AMC
  • AMC (Vrijgesteld)
  • Radboud Universiteit Nijmegen
  • ZonMw